Cargando…
Can CD147 work as a therapeutic target for tumors through COVID-19 infection?
In this review, we discussed an interesting case infected with “COVID-19” (Corona Virus Disease 2019). The patients with Hodgkin's lymphoma recovered after infection with COVID-19. It may be that COVID-19 activates the patient's immune system, or it may be a coincidence. COVID-19 spike pro...
Autores principales: | Ren, Hao-Lin, Wen, Gui-Min, Zhao, Zhen-Ying, Liu, Da-Hua, Xia, Pu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724241/ https://www.ncbi.nlm.nih.gov/pubmed/36483594 http://dx.doi.org/10.7150/ijms.79162 |
Ejemplares similares
-
Generation of a High-Affinity Nanobody Against CD147 for Tumor Targeting and Therapeutic Efficacy Through Conjugating Doxorubicin
por: Li, Rifei, et al.
Publicado: (2022) -
Targeting CD147 for T to NK Lineage Reprogramming and Tumor Therapy
por: Geng, Jie-Jie, et al.
Publicado: (2017) -
Mini-Review: Can the Metastatic Cascade Be Inhibited by Targeting CD147/EMMPRIN to Prevent Tumor Recurrence?
por: Rahat, Michal A.
Publicado: (2022) -
Role of melatonin in the treatment of COVID-19; as an adjuvant through cluster differentiation 147 (CD147)
por: Sehirli, Ahmet Ozer, et al.
Publicado: (2020) -
CD147 Promotes CXCL1 Expression and Modulates Liver Fibrogenesis
por: Shi, Wen-Pu, et al.
Publicado: (2018)